The choice of polymyxin B as the antibiotic partner in this combination deserves particular attention. Polymyxins are among the last-resort antibiotics for Gram-negative infections, acting by binding to lipopolysaccharide in the outer membrane and disrupting membrane integrity. Yet their clinical utility has been constrained by nephrotoxicity concerns and, increasingly, by the spread of plasmid-borne resistance genes such as mcr variants that have circulated through livestock and food production systems. An adjuvant that restores or potentiates polymyxin susceptibility could allow lower effective doses of the antibiotic, potentially reducing both the toxic burden on patients and the selective pressure that drives resistance dissemination. The study’s systematic screening across a panel of eight antibiotics, including tetracycline, ciprofloxacin, gentamicin, aztreonam, ceftriaxone, cefotaxime, and doxycycline, provides a rational basis for selecting the most synergistic pairing rather than relying on arbitrary combination choices.

Piceatannol itself brings an interesting pharmacological profile to this partnership. As a hydroxylated analogue of resveratrol, the well-known stilbene of red grape fame, it shares the polyphenolic scaffold that has made these compounds subjects of intense investigation across multiple fields of biomedical research. Its documented antioxidant and anti-inflammatory activities suggest it might offer secondary benefits in the context of intestinal infection, where oxidative and inflammatory damage to the gut epithelium contributes substantially to disease severity. The compound is most abundantly available from passion fruit seeds, though it also occurs in grapes and various other plant sources, raising the possibility of relatively accessible supply chains if therapeutic applications were ever developed. The researchers sourced their material from a commercial supplier and dissolved it in dimethyl sulfoxide for experimental use, maintaining solvent concentrations below one percent to avoid confounding effects on bacterial physiology.

The experimental design reflects careful attention to the distinctive biology of biofilm-associated infection. Rather than relying solely on planktonic growth inhibition, the team employed crystal violet staining to quantify biofilm biomass, a classical method that measures the adherence of bacterial communities to abiotic surfaces. They complemented this with assessments of metabolic viability within the biofilm, recognizing that biomass measurements alone can be misleading when compounds alter matrix production without necessarily affecting cell numbers. The focus on swarming motility is particularly noteworthy. Swarming is a flagellum-dependent form of surface translocation that requires coordinated behavior across bacterial populations, and it is intimately linked to the early stages of surface colonization that precede mature biofilm development. By demonstrating that piceatannol suppresses this motility, the researchers identified a mechanism that operates upstream of biofilm maturation, potentially preventing the establishment of resilient communities before they become entrenched.

The characterization of exopolysaccharide and extracellular protein production adds mechanistic depth to these observations. Exopolysaccharides form the structural backbone of the biofilm matrix, creating the hydrated scaffold within which cells are embedded and protected from external threats. Extracellular proteins contribute to matrix stability, facilitate adhesion, and participate in the communication networks that coordinate community behavior. Reducing the production of both components would be expected to yield a structurally weakened biofilm, one more permeable to antibiotics and more vulnerable to immune clearance. This mechanistic understanding aligns with the observed enhancement of polymyxin B efficacy, since the positively charged polymyxin molecule must physically reach the bacterial outer membrane to exert its lethal effect, and a compromised matrix would facilitate that access.

The murine infection model provides the critical translational bridge from in vitro observations to potential clinical relevance. By assessing bacterial loads in the liver and spleen, the researchers gained insight into systemic dissemination, a key concern in E. coli O157 infections where bacteremia can complicate the clinical course. The evaluation of ileal villous morphology addresses the intestinal pathology that characterizes this infection, since the attachment and effacement lesions that E. coli O157 produces on intestinal epithelium are central to its disease mechanism. Improved villous architecture in treated animals suggests that the combination therapy not only reduced bacterial burden but also mitigated the tissue damage that the infection inflicts on the gut lining. Survival outcomes, the ultimate measure of therapeutic efficacy, showed clear superiority of the combination over either agent alone.

The restriction of the in vitro work to a single reference strain, ATCC 43895 carrying both stx1 and stx2 genes, represents both a strength and a limitation worth considering. This strain is a well-characterized laboratory standard whose behavior is highly reproducible, lending confidence to the mechanistic findings. However, clinical isolates of E. coli O157 display considerable genetic diversity, and their biofilm-forming capacities, motility characteristics, and antibiotic susceptibility profiles can vary substantially. Whether the piceatannol-polymyxin B synergy extends across this diversity remains an open question that future studies will need to address. Similarly, the pharmacokinetic behavior of piceatannol in mammals, including its absorption, metabolism, and distribution to intestinal tissues, will require detailed characterization before any therapeutic application can be contemplated.

The broader significance of this work lies in its contribution to the growing recognition that antivirulence strategies represent a complementary approach to traditional antibiotic development. Rather than seeking to kill bacteria outright, antivirulence agents disarm the mechanisms by which pathogens establish infection and resist clearance. This approach theoretically imposes weaker selective pressure for resistance, since the compound does not directly threaten bacterial survival in the same way that bactericidal antibiotics do. The biofilm context is especially relevant here, as the tolerance that biofilm-resident cells exhibit toward antibiotics stems from their physiological state and protective matrix rather than from acquired resistance genes. Disrupting the biofilm lifestyle itself, as piceatannol appears to do, addresses this distinct form of treatment failure that conventional susceptibility testing fails to capture.

Looking forward, the findings open several avenues for continued investigation. Understanding the precise molecular targets through which piceatannol suppresses swarming motility and matrix production would strengthen the mechanistic foundation and potentially reveal conserved regulatory pathways amenable to broader intervention. Exploring whether the compound synergizes with other antibiotic classes or with non-antibiotic therapeutic modalities could expand its utility. Testing against additional Shiga toxin-producing E. coli serotypes and other biofilm-forming enteric pathogens would clarify the generality of the approach. And establishing appropriate dosing regimens, safety profiles, and potential interactions with the complex intestinal environment will be essential steps toward any translational application. For now, the study stands as a compelling demonstration that natural product chemistry, thoughtfully paired with existing antibiotics, can yield combination strategies that address the multifaceted challenges posed by biofilm-associated foodborne pathogens.

Subject of Research: Piceatannol enhances polymyxin B efficacy against Escherichia coli O157:H7 via inhibition of biofilm formation

Article Title: Piceatannol enhances polymyxin B efficacy against Escherichia coli O157:H7 via inhibition of biofilm formation

Article References: Xu, J., Zhou, Y., Bao, W., Ma, Z., Shang, Z., Zhang, H., Wang, W., Li, B., Bai, Y., & Zhang, J. (2026). Piceatannol enhances polymyxin B efficacy against Escherichia coli O157:H7 via inhibition of biofilm formation. Frontiers in Microbiology, 17, Article 1933569. https://doi.org/10.3389/fmicb.2026.1933569

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1933569

Keywords: Escherichia coli O157:H7, piceatannol, polymyxin B, biofilm, antimicrobial resistance, Shiga toxin, exopolysaccharides, swarming motility, antibiotic adjuvant, murine infection model, Frontiers in Microbiology, enhances

Diabetic retinopathy is a devastating complication of diabetes, characterized by progressive damage to the microvascular network that nourishes the light-sensitive tissue at the back of the eye. For decades, clinicians have focused their attention on the blood vessels themselves, treating the leaky capillaries and abnormal new vessel growth with laser therapy, injections of anti-VEGF drugs, or surgery. But a growing body of evidence points to a quieter culprit: chronic neuroinflammation, driven in large part by microglia, the resident immune cells of the retina. When these cells become chronically activated in a high-glucose environment, they release a cocktail of pro-inflammatory cytokines that erode the structural and functional integrity of the retinal vasculature from the outside in.

The research team approached the problem with an unusually systematic strategy. Rather than testing piceatannol blindly, they combined network pharmacology with transcriptomic analysis to map the compound’s potential molecular targets against the gene signatures of diabetic retinopathy. The computational screen identified 159 overlapping targets shared between the polyphenol and the disease. Among these, one receptor rose to the top: C-C chemokine receptor type 5, or CCR5, a G protein-coupled receptor best known to immunologists for its role in directing immune cell traffic and, famously, as an entry co-receptor exploited by HIV.

Molecular docking studies predicted that piceatannol could bind directly to CCR5, and the researchers went on to validate that binding affinity experimentally. This mattered because the receptor’s ligand, the chemokine CCL5, was significantly upregulated in the diabetic retina. The picture that emerged was of a signaling cascade, CCL5 binding to CCR5 and triggering the pro-inflammatory transcription factor NF-κB, that could potentially be intercepted at its receptor by a dietary polyphenol. Single-cell and expression analyses added a crucial layer of specificity: CCR5 was found to be expressed predominantly in retinal microglia, placing the immune cells squarely at the center of the pathway.

To test the compound’s effects, the team built disease models at two scales. In the laboratory, they exposed microglia to high glucose concentrations to mimic the diabetic metabolic environment. In living animals, they induced diabetes in mice using streptozotocin, a chemical that destroys insulin-producing cells and produces sustained hyperglycemia. The results in the animals were striking. Mice treated with piceatannol showed restored retinal thickness, reduced formation of acellular capillaries, the ghost vessels that mark dead capillary segments in diabetic retinas, and attenuated vascular leakage, the pathological seepage of fluid and proteins that ultimately destroys vision.

The cellular mechanism behind these improvements centered on microglial polarization. Microglia, like their peripheral cousins the macrophages, can adopt broadly two functional states. The M1 phenotype is pro-inflammatory, unleashing tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6, along with inducible nitric oxide synthase, all of which batter neighboring tissue. The M2 phenotype is restorative, promoting tissue repair through markers such as arginase-1, interleukin-10 and transforming growth factor beta 1. In the diabetic retina, the balance tips decisively toward M1. Piceatannol treatment, the researchers found, inhibited microglial activation and M1 polarization, reduced the secretion of pro-inflammatory cytokines, and promoted the expression of M2-associated markers, all through modulation of the CCL5/CCR5/NF-κB signaling pathway.

The downstream consequences for blood vessels were equally telling. In vitro experiments using human retinal endothelial cells showed that when high glucose pushed co-cultured microglia into their inflammatory state, the endothelial cells suffered: the tight junction proteins zonula occludens-1 and Claudin-5, which zip adjacent endothelial cells together to form the inner blood-retinal barrier, were degraded. Piceatannol suppressed the high-glucose-induced M1 polarization of the microglia and, as a result, preserved the expression of these tight junction proteins. In other words, the compound’s vascular protection appears to be indirect, mediated through the immune cells rather than through a direct effect on the endothelium itself.

The team then put the CCR5 hypothesis to a rigorous causal test. Using small interfering RNA to knock down CCR5 expression, and separately employing pharmacological activation of the receptor, they confirmed that CCR5 sits at the center of the protective mechanism. When the receptor was silenced, piceatannol’s benefits were diminished or recapitulated by the knockdown itself; when the pathway was artificially activated, the compound’s protective effects were counteracted. This pattern of gain- and loss-of-function evidence strengthens the argument that the CCL5/CCR5/NF-κB axis is not merely correlated with the disease process but is functionally required for the drug’s action.

The significance of the work lies partly in its translational framing. Piceatannol is a naturally occurring stilbenoid, meaning it is already present in the human food supply and has been studied for anti-inflammatory and vascular-protective properties in other contexts. Demonstrating a concrete, mechanistically defined role in diabetic retinopathy raises the possibility of repurposing a well-characterized molecule for a condition that currently affects tens of millions of people worldwide. The network pharmacology approach also offers a template for how natural products with dozens of potential targets can be systematically triaged, using docking, transcriptomics and weighted gene co-expression network analysis to converge on the handful of targets that actually matter.

Substantial caveats remain before patients should expect a piceatannol-based therapy. The findings come from cell culture and streptozotocin-induced mouse models, which reproduce key features of diabetic retinopathy but do not capture the full complexity of human disease, which unfolds over decades of metabolic stress. Questions about bioavailability, dosing, retinal drug delivery and long-term safety in a diabetic population remain open, and the study was funded by Chinese national and municipal science programs without reported involvement of commercial drug development. Still, by pinpointing a druggable receptor on retinal microglia and showing that a food-derived polyphenol can restrain the inflammatory cascade that dismantles the blood-retinal barrier, the study adds a compelling new chapter to the growing recognition that diabetic blindness is as much an immunological disease as a vascular one.

Subject of Research: The role of piceatannol in modulating microglial polarization via the CCL5/CCR5/NF-κB axis to protect retinal endothelial cells in diabetic retinopathy

Article Title: Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis

Article References: Tu, Y., Guo, Y., Zhang, Y., Sun, H., Zhu, X., Shen, G., Gu, Y., Xie, L., Song, E., & Zhu, M. (2026). Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08893-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08893-6

Keywords: diabetic retinopathy, piceatannol, microglial polarization, CCR5, CCL5, NF-κB, retinal endothelial cells, blood-retinal barrier, neuroinflammation, tight junctions, network pharmacology, resveratrol